source
- FDA approves Takeda's orexin drug for narcolepsy type 1Takeda has received FDA approval for its orexin agonist intended to treat narcolepsy type 1. The decision ends a closely watched commercial race to bring an orexin-based therapy to market. With a…
- Attovia Therapeutics raises $289 million in IPO to fund antibody-drug research for skin and inflammatory diseasesAttovia Therapeutics completed an IPO raising $289 million, selling 17 million shares at $17 each and valuing the company at $767 million. Shares will begin trading on Nasdaq under the ticker ATTO.…